Exact Sciences and Flatiron Health, a healthtech company dedicated to improving cancer care and advancing research, are partnering to accelerate clinical evidence generation for Exact Sciences’ molecular residual disease test (MRD) Oncodetect, the company announced recently.

“Our collaboration with Flatiron Health represents a significant step in advancing cancer diagnostics, with a particular focus on MRD,” Exact Sciences General Manager of Precision Oncology Brian Baranick said in a statement. “The partnership will generate robust clinical evidence for the Oncodetect test across multiple solid tumor types, helping improve cancer recurrence monitoring and ensuring our innovations address patient needs for better outcomes.”

According to a release, the partnership leverages Flatiron’s clinical research platform to study a broad range of solid tumor types.

The two companies already have the study’s first patient enrolled. The study looks to evaluate the use of a tumor-informed ctDNA test for detecting MRD and predicting cancer recurrence in solid tumors.